Is RLF.SW stock a buy after the recent bounce?

RLF.SW stock shows a short-term bounce, but fundamentals remain negative. Consider a tactical trade above CHF3.00 and a stop under CHF2.50. Long-term buyers should wait for clear trial or earnings progress.

What catalysts could move Relief Therapeutics (RLF.SW)?

Key catalysts are the earnings update on 08 Apr 2026 and clinical data for RLF-100 and other pipeline assets. Positive trial results or clearer funding guidance would materially change the outlook.

How does Meyka AI rate RLF.SW stock?

Meyka AI rates RLF.SW at **64.76 out of 100** (Grade B, HOLD). This score factors in benchmarks, sector performance, growth, key metrics, forecasts, and analyst signals.

What price targets should traders use for RLF.SW stock?

For an oversold-bounce trade use a near-term target **CHF3.50**, a conservative target **CHF4.50**, and a stop between **CHF2.20–CHF2.50** depending on risk tolerance.

CH Stocks

CHF2.885 close: Relief Therapeutics RLF.SW (SIX) bounce before earnings Mar 2026

ByHuzaifa Zahoor March 18, 2026March 18, 2026

RLF.SW stock closed at CHF2.885 on 17 Mar 2026 after a modest intraday gain, setting up a classic oversold bounce in the biotech name. Relief Therapeutics Holding AG (RLF.SW) on the SIX exchange traded 66,704.00 shares today, above its 50-day average and showing relative volume 1.62, a sign of renewed buying interest. The company still posts negative EPS -1.36 and a negative PE -2.12, but liquidity metrics and an upcoming earnings date on 08 Apr 2026 make the current pullback a near-term trading setup. We assess valuation, catalysts, and Meyka AI forecasts to frame a pragmatic oversold-bounce strategy for traders and investors.